RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, EW, IDXX, and RMD
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and ResMed (RMD). These companies are all part of the "medical" sector.
ReShape Lifesciences vs. Its Competitors
ReShape Lifesciences (NASDAQ:RSLS) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.
bioAffinity Technologies has a consensus price target of $6.00, indicating a potential upside of 1,835.48%. Given bioAffinity Technologies' higher possible upside, analysts clearly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.
ReShape Lifesciences has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.
In the previous week, bioAffinity Technologies had 1 more articles in the media than ReShape Lifesciences. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for ReShape Lifesciences. ReShape Lifesciences' average media sentiment score of 0.57 beat bioAffinity Technologies' score of -0.66 indicating that ReShape Lifesciences is being referred to more favorably in the media.
ReShape Lifesciences has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.
22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 0.0% of ReShape Lifesciences shares are owned by company insiders. Comparatively, 16.9% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.
Summary
ReShape Lifesciences and bioAffinity Technologies tied by winning 7 of the 14 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
This page (NASDAQ:RSLS) was last updated on 7/10/2025 by MarketBeat.com Staff
